Oppenheimer reaffirmed their hold rating on shares of Axovant Sciences (NASDAQ:AXON) in a research note issued to investors on Sunday, November 12th. Oppenheimer also issued estimates for Axovant Sciences’ Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($2.34) EPS, FY2019 earnings at ($2.00) EPS, FY2020 earnings at ($1.54) EPS and FY2022 earnings at ($0.79) EPS.
A number of other equities analysts have also recently weighed in on the company. BidaskClub cut Axovant Sciences from a sell rating to a strong sell rating in a report on Friday, September 15th. Evercore ISI started coverage on Axovant Sciences in a report on Friday, September 8th. They set an outperform rating and a $30.00 price target for the company. Zacks Investment Research upgraded Axovant Sciences from a hold rating to a strong-buy rating and set a $8.00 price target for the company in a report on Monday, October 9th. HC Wainwright reiterated a buy rating on shares of Axovant Sciences in a report on Thursday, October 19th. Finally, Chardan Capital reiterated a sell rating and set a $3.00 price target on shares of Axovant Sciences in a report on Saturday, September 23rd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $14.13.
Shares of Axovant Sciences (NASDAQ AXON) traded down $0.12 during mid-day trading on Friday, hitting $5.40. The stock had a trading volume of 803,584 shares, compared to its average volume of 1,018,484. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with our FREE daily email newsletter.